首页> 外国专利> POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ACETAMINOPHEN AND RELATED COMPOUNDS WITH VERY FAST SKIN PENETRATION RATE

POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ACETAMINOPHEN AND RELATED COMPOUNDS WITH VERY FAST SKIN PENETRATION RATE

机译:乙酰氨基酚及相关化合物的带正电荷的水溶性很高的皮肤穿透率的产品

摘要

The novel positively charged pro-drugs of acetaminophen, acetaminosalol, and related compounds in the general formula (1) 'Structure 1' were designed and synthesized. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin ˆ¼150 times faster than does acetaminophen, acetaminosalol, and related compounds. It takes 1-2 hours for acetaminophen and acetaminosalol, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about ˆ¼50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can be changed back to the parent drugs in a few minutes. The prodrugs can be used medicinally for treating any NSAIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of NSAIAs. Controlled transdermal administration systems of the prodrugs enables acetaminophen, acetaminosalol, and related compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of acetaminophen, acetaminosalol, and related compounds. Another great benefit of transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.
机译:设计并合成了通式(1)“结构1”中对乙酰氨基酚,对乙酰氨基酚和相关化合物的新型带正电荷的前药。这些前药的带正电荷的氨基基团不仅大大增加了药物的溶解度,而且还与膜的磷酸盐头基团上的负电荷键合并将前药推入细胞质。结果表明,前药在人皮肤中的扩散速度比对乙酰氨基酚,对乙酰氨基酚和相关化合物快1/4倍。对乙酰氨基酚和对乙酰氨基酚以及相关化合物口服时需要1-2小时才能达到血浆峰值水平,而经皮服用时,这些前药仅需约¼50分钟即可达到血浆峰值水平。在血浆中,超过90%的这些前药可以在几分钟内变回母体药物。前药可用于治疗人或动物的任何NSAIA可治疗的疾病。前药不仅可以口服,而且可以透皮给药用于任何类型的药物治疗,并且可以避免NSAIA的大多数副作用。前药的受控透皮给药系统使对乙酰氨基酚,对乙酰氨基酚和相关化合物能够不断达到最佳的治疗血药水平,从而提高疗效并减少对乙酰氨基酚,对乙酰氨基酚和相关化合物的副作用。这些前药的透皮给药的另一大好处是,尤其是对儿童给药更容易。

著录项

  • 公开/公告号EP2061749B1

    专利类型

  • 公开/公告日2018-02-21

    原文格式PDF

  • 申请/专利权人 TECHFIELDS BIOCHEM CO LTD;YU CHONGXI;

    申请/专利号EP20060795894

  • 发明设计人 XU LINA;YU CHONGXI;

    申请日2006-09-03

  • 分类号C07C233/25;A61K31/167;A61K31/22;A61P29/00;A61P11/06;A61P35/00;A61P27/06;A61P27/16;A61P17/00;

  • 国家 EP

  • 入库时间 2022-08-21 13:19:10

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号